From Evidence to Effectiveness: Implications of the Randomized Trial to Prevent Vascular Events in HIV Study for People With Human Immunodeficiency Virus in Low- and Middle-Income Settings

Jennifer Manne-Goehler; Mohammed K Ali; David Flood; Vincent C Marconi; Willem D F Venter; Mark J Siedner

doi:10.1093/cid/ciad702

From Evidence to Effectiveness: Implications of the Randomized Trial to Prevent Vascular Events in HIV Study for People With Human Immunodeficiency Virus in Low- and Middle-Income Settings

Clin Infect Dis. 2023 Dec 8:ciad702. doi: 10.1093/cid/ciad702. Online ahead of print.

Authors

Jennifer Manne-Goehler^{1

2}, Mohammed K Ali^{3

4

5}, David Flood⁶, Vincent C Marconi^{4

7}, Willem D F Venter⁸, Mark J Siedner^{2

9

10}

Affiliations

¹ Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Emory Global Diabetes Research Center of Woodruff Health Sciences Center and Emory University, Atlanta, Georgia, USA.
⁴ Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
⁵ Department of Family and Preventive Medicine, School of Medicine, Emory University, Georgia, USA.
⁶ Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
⁷ Division of Infectious Diseases, Emory University School of Medicine, Emory University, Atlanta, Georgia, USA.
⁸ Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
⁹ Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹⁰ Clinical Research Department, Africa Health Research Institute, KwaZulu-Natal, South Africa.

PMID: 38066673
DOI: 10.1093/cid/ciad702

Abstract

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study found a 35% reduction in major adverse cardiovascular events for people with human immunodeficiency virus who received daily pitavastatin. However, how this evidence will change practice is far from certain. Here, we outline evidence gaps and political and healthcare delivery challenges that will need to be addressed for REPRIEVE to offer public health benefits in low- and middle-income countries.

Keywords: HIV; cardiovascular disease; integrated care.

Abstract

Grants and funding